Nauka i technologie

Raport bieżący z plikiem 28/2017

<ul>
<li>First oral short-course treatment for highly active relapsing multiple sclerosis (RMS)[1] now approved in Europe</li>
<li>MAVENCLAD® has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years</li>
<li>Marketing authorization includes the 28 countries of the European Union (EU), with first launches in the UK and in Germany</li>
</ul>